Journal of Dermatological Treatment · Available online 11 May 2026 · In press · DOI 10.1080/09546634.2026.2665961
Eric L. Simpson, Vimal H. Prajapati, Christopher G. Bunick, Raj Chovatiya, Linda F. Stein Gold, Ignasi Figueras Nart, Brian Calimlim, Ayman Grada, Alena Pechonkina, Chao Li, Bang Truong, Xiaofei Hu, Yolanda Armendariz, Norito Katoh
Objectives Atopic dermatitis (AD), a chronic, immune-mediated inflammatory disease, is characterized by intense itch, eczematous rash, and skin pain, which can have negative impacts to quality-of-life (QoL), sleep, and mental health (especially anxiety and depression). Evaluation of the impacts of AD on the patient’s lived experience are most accurately assessed by the patient, making measures of patient-reported outcomes (PROs) indispensable. The objective of the current study was to assess the long-term impact of upadacitinib, a once-daily oral selective Janus kinase inhibitor approved for the treatment of moderate-to-severe AD, on patient-reported outcomes, providing a comprehensive in-depth evaluation of results of patient experience across multiple domains.Methods Using integrated data from the Measure Up 1 & 2 trials, the current study characterizes the efficacy of upadacitinib on several measures that assess the impact of AD on patients’ lives, including patient-reported disease and symptom severity, sleep, emotional well-being, daily activities, QoL, and treatment satisfaction.Results Results demonstrated that rapid improvements in PRO measures of itch, sleep, daily activities, QoL, and emotional well-being reported at week 16 and week 52 were sustained or further improved at week 140 for patients with moderate-to-severe AD continuing upadacitinib 15 mg or 30 mg therapy, with no new safety signals observed.Conclusions These findings support upadacitinib as a long-term treatment option to improve patient-reported burdensome symptoms of AD across 140 weeks of exposure.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Simpson, E., Prajapati, V., Bunick, C., et al. (2026). Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials. Journal of Dermatological Treatment. https://doi.org/10.1080/09546634.2026.2665961